Jubilant Pharmova Limited on Friday announced that its wholly owned US subsidiary, Jubilant HollisterStier LLC (JHS), has successfully launched a new sterile fill and finish line at its Spokane manufacturing facility in Washington, US.
The new high-speed isolator-based line, the third at the facility, marks a major milestone in the company’s multi-phase expansion strategy and brings an additional 50% capacity increase to the Spokane site.
Built with advanced isolator technology, the new line enhances sterility assurance, throughput, and operational precision, while meeting the highest global regulatory standards. The $132 million investment reflects Jubilant’s long-term commitment to innovation, quality, and supply chain resilience.
Commenting on the launch, Chris Preti, CEO – CDMO Sterile Injectables, said, “Launching our Third Line is a defining moment for Jubilant HollisterStier. With the Fourth Line on the horizon, we’re building a future that will create hundreds of new jobs, strengthen the US pharmaceutical supply chain, and reaffirm our role as a trusted partner in delivering life-saving therapies.”
Preti added that the company is seeing strong request-for-proposal (RFP) traction from large innovator pharma companies following new US government tariffs, as firms seek high-quality domestic manufacturing facilities. JHS expects full utilization of the new line within three years.
Together with the upcoming Fourth Line, the Spokane facility is on track to double its total sterile injectable manufacturing capacity, reinforcing Jubilant’s leadership in the North American contract manufacturing market.
JHS currently partners with five of the top 20 global pharma companies and has a 92% customer retention rate, underscoring its strong reputation for quality and reliability. The company operates facilities in Spokane (Washington) and Montréal (Québec), serving clients in over 140 countries.
Jubilant Pharmova said the expansion aligns with its broader mission to strengthen onshore pharmaceutical manufacturing, contribute to US national health security, and reduce reliance on offshore supply chains.
